Perspectives in medicinal chemistry: Why do we need new drug classes for HIV treatment and prevention?

Current Topics in Medicinal Chemistry

Volumn 16, Issue 12, 2016, Pages 1343-1349

  Waheed, Abdul A ^a   Tachedjian, Gilda ^b,c,d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b BURNET INSTITUTE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Antiretroviral therapy; Drug discovery; Drug resistance; HIV; Host cell factors; Pre exposure prophylaxis

Indexed keywords

ALBUVIRTIDE; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CABOTEGRAVIR; CARBOTEGRAVIR; CENICRIVIROC; CHEMOKINE RECEPTOR CCR5; DOLUTEGRAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HOST FACTOR; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IBALIZUMAB; INTEGRASE INHIBITOR; NEF PROTEIN; NEW DRUG; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; TENOFOVIR ALAFENAMIDE; UNCLASSIFIED DRUG; VIF PROTEIN; VPU PROTEIN; VPX PROTEIN; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRE-EXPOSURE PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT FAILURE; VIRAL LOAD TESTING; VIRUS ATTACHMENT; VIRUS CELL INTERACTION; VIRUS REPLICATION; CHEMISTRY; CLASSIFICATION; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; SYNTHESIS; VIROLOGY;

ANTIVIRAL AGENTS; HIV; HIV INFECTIONS; HUMANS; VIRUS REPLICATION;

EID: 84961692436     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026616999151013124606     Document Type: Article

References (73)

1. Barre-Sinoussi, F.; Chermann, J. C.; Rey, F.; Nugeyre, M. T.; Chamaret, S.; Gruest, J.; Dauguet, C.; Axler-Blin, C.; Vezinet- Brun, F.; Rouzioux, C.; Rozenbaum, W.; Montagnier, L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science, 1983, 220 (4599), 868-871.
2. Samji, H.; Cescon, A.; Hogg, R. S.; Modur, S. P.; Althoff, K. N.; Buchacz, K.; Burchell, A. N.; Cohen, M.; Gebo, K. A.; Gill, M. J.; Justice, A.; Kirk, G.; Klein, M. B.; Korthuis, P. T.; Martin, J.; Napravnik, S.; Rourke, S. B.; Sterling, T. R.; Silverberg, M. J.; Deeks, S.; Jacobson, L. P.; Bosch, R. J.; Kitahata, M. M.; Goedert, J. J.; Moore, R.; Gange, S. J. North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA., Closing the gap: Increases in life expectancy among treated HIVpositive individuals in the United states and Canada. PLoS One, 2013, 8 (12), e81355.
3. Hammer, S. M.; Squires, K. E.; Hughes, M. D.; Grimes, J. M.; Demeter, L. M.; Currier, J. S.; Eron, J. J., Jr.; Feinberg, J. E.; Balfour, H. H., Jr.; Deyton, L. R.; Chodakewitz, J. A.; Fischl, M. A. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N. Engl. J. Med., 1997, 337 (11), 725-733.
4. Cohen, M. S.; Chen, Y. Q.; McCauley, M.; Gamble, T.; Hosseinipour, M. C.; Kumarasamy, N.; Hakim, J. G.; Kumwenda, J.; Grinsztejn, B.; Pilotto, J. H.; Godbole, S. V.; Mehendale, S.; Chariyalertsak, S.; Santos, B. R.; Mayer, K. H.; Hoffman, I. F.; Eshleman, S. H.; Piwowar-Manning, E.; Wang, L.; Makhema, J.; Mills, L. A.; de Bruyn, G.; Sanne, I.; Eron, J.; Gallant, J.; Havlir, D.; Swindells, S.; Ribaudo, H.; Elharrar, V.; Burns, D.; Taha, T. E.; Nielsen-Saines, K.; Celentano, D.; Essex, M.; Fleming, T. R. Prevention of HIV-1 infection with early antiretroviral therapy. N. Engl. J. Med., 2011, 365 (6), 493-505.
5. Piot, P.; Abdool Karim, S. S.; Hecht, R.; Legido-Quigley, H.; Buse, K.; Stover, J.; Resch, S.; Ryckman, T.; Mogedal, S.; Dybul, M.; Goosby, E.; Watts, C.; Kilonzo, N.; McManus, J.; Sidibe, M. Defeating AIDS--advancing global health. Lancet, 2015, 386 (9989), 171-218.
6. Latham, C. F.; La, J.; Tinetti, R. N.; Chalmers, D. K.; Tachedjian, G. Fragment based strategies for discovery of novel HIV-1 reverse transcriptase and integrase inhibitors. Curr. Top. Med. Chem., in press.
7. Gallant, J. E.; De Jesus, E.; Arribas, J. R.; Pozniak, A. L.; Gazzard, B.; Campo, R. E.; Lu, B.; McColl, D.; Chuck, S.; Enejosa, J.; Toole, J. J.; Cheng, A. K. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N. Engl. J. Med., 2006, 354 (3), 251-260.
8. Blanco, J. L.; Montaner, J. S.; Marconi, V. C.; Santoro, M. M.; Campos-Loza, A. E.; Shafer, R. W.; Miller, M. D.; Paredes, R.; Harrigan, R.; Nguyen, M. L.; Perno, C. F.; Gonzalez-Hernandez, L. A.; Gatell, J. M. Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovir + emtricitabine/lamivudine + efavirenz administered on a multiple tablet therapy. AIDS, 2014, 28 (17), 2531-2539.
9. Lundgren, J.; Babiker, A.; Gordin, F.; Emery, S.; Fatkenheuer, G.; Molina, J. M.; Wood, R.; Neaton, J. D. Why START? Reflections that led to the conduct of this large long-term strategic HIV trial. HIV. Med., 2015, 16 Suppl 1, 1-9.
10. Fletcher, C. V.; Staskus, K.; Wietgrefe, S. W.; Rothenberger, M.; Reilly, C.; Chipman, J. G.; Beilman, G. J.; Khoruts, A.; Thorkelson, A.; Schmidt, T. E.; Anderson, J.; Perkey, K.; Stevenson, M.; Perelson, A. S.; Douek, D. C.; Haase, A. T.; Schacker, T. W. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc. Natl. Acad. Sci. U.S.A., 2014, 111 (6), 2307-2312.
11. Sax, P. E.; Wohl, D.; Yin, M. T.; Post, F.; DeJesus, E.; Saag, M.; Pozniak, A.; Thompson, M.; Podzamczer, D.; Molina, J. M.; Oka, S.; Koenig, E.; Trottier, B.; Andrade-Villanueva, J.; Crofoot, G.; Custodio, J. M.; Plummer, A.; Zhong, L.; Cao, H.; Martin, H.; Callebaut, C.; Cheng, A. K.; Fordyce, M. W.; McCallister, S. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: Two randomised, doubleblind, phase 3, non-inferiority trials. Lancet, 2015, 385 (9987), 2606-2615.
12. Raffi, F.; Rachlis, A.; Brinson, C.; Arasteh, K.; Gorgolas, M.; Brennan, C.; Pappa, K.; Almond, S.; Granier, C.; Nichols, W. G.; Cuffe, R. L.; Eron, J., Jr.; Walmsley, S. Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials. AIDS, 2015, 29 (2), 167-174.
13. Margolis, D. A.; Brinson, C. C.; Smith, G. H.; de Vente, J.; Hagins, D. P.; Eron, J. J.; Griffith, S. K.; Clair, M. H.; Stevens, M. C.; Williams, P. E.; Ford, S. L.; Stancil, B. S.; Bomar, M. M.; Hudson, K. J.; Smith, K. Y.; Spreen, W. R. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): A randomised, phase 2b, dose-ranging trial. Lancet Infect. Dis., 2015, 15(10), 1145-1155.
14. La, J.; Latham, C. F.; Tinetti, R. N.; Johnson, A.; Tyssen, D.; Huber, K. D.; Sluis-Cremer, N.; Simpson, J. S.; Headey, S. J.; Chalmers, D. K.; Tachedjian, G. Identification of mechanistically distinct inhibitors of HIV-1 reverse transcriptase through fragment screening. Proc. Natl. Acad. Sci. U.S.A., 2015, 112 (22), 6979-6984.
15. Bauman, J. D.; Patel, D.; Dharia, C.; Fromer, M. W.; Ahmed, S.; Frenkel, Y.; Vijayan, R. S.; Eck, J. T.; Ho, W. C.; Das, K.; Shatkin, A. J.; Arnold, E. Detecting allosteric sites of HIV-1 reverse transcriptase by X-ray crystallographic fragment screening. J. Med. Chem., 2013, 56 (7), 2738-2746.
16. Tiefenbrunn, T.; Forli, S.; Happer, M.; Gonzalez, A.; Tsai, Y.; Soltis, M.; Elder, J. H.; Olson, A. J.; Stout, C. D. Crystallographic fragment-based drug discovery: Use of a brominated fragment library targeting HIV protease. Chem. Biol. Drug Des., 2014, 83 (2), 141-148.
17. Brass, A. L.; Dykxhoorn, D. M.; Benita, Y.; Yan, N.; Engelman, A.; Xavier, R. J.; Lieberman, J.; Elledge, S. J. Identification of host proteins required for HIV infection through a functional genomic screen. Science, 2008, 319 (5865), 921-926.
18. Konig, R.; Zhou, Y.; Elleder, D.; Diamond, T. L.; Bonamy, G. M.; Irelan, J. T.; Chiang, C. Y.; Tu, B. P.; De Jesus, P. D.; Lilley, C. E.; Seidel, S.; Opaluch, A. M.; Caldwell, J. S.; Weitzman, M. D.; Kuhen, K. L.; Bandyopadhyay, S.; Ideker, T.; Orth, A. P.; Miraglia, L. J.; Bushman, F. D.; Young, J. A.; Chanda, S. K. Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell, 2008, 135 (1), 49-60.
19. Zhou, H.; Xu, M.; Huang, Q.; Gates, A. T.; Zhang, X. D.; Castle, J. C.; Stec, E.; Ferrer, M.; Strulovici, B.; Hazuda, D. J.; Espeseth, A. S. Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe., 2008, 4 (5), 495-504.
20. Drake, M. J.; Bates, P. Application of gene-editing technologies to HIV-1. Curr. Opin. HIV AIDS, 2015, 10 (2), 123-127.
21. Roche, M.; Borm, K.; Flynn, J. K.; Lewin, S. R.; Churchill, M. J.; Gorry, P. R. Molecular gymnastics: Mechanisms of HIV-1 resistance to ccr5 antagonists and impact on virus phenotypes. Curr. Top. Med. Chem., in press.
22. Christ, F.; Voet, A.; Marchand, A.; Nicolet, S.; Desimmie, B. A.; Marchand, D.; Bardiot, D.; Van der Veken, N. J.; Van Remoortel, B.; Strelkov, S. V.; De Maeyer, M.; Chaltin, P.; Debyser, Z. Rational design of small-molecule inhibitors of the LEDGF/p75- integrase interaction and HIV replication. Nat. Chem. Biol., 2010, 6 (6), 442-448.
23. Jurado, K. A.; Wang, H.; Slaughter, A.; Feng, L.; Kessl, J. J.; Koh, Y.; Wang, W.; Ballandras-Colas, A.; Patel, P. A.; Fuchs, J. R.; Kvaratskhelia, M.; Engelman, A. Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation. Proc. Natl. Acad. Sci. U.S.A., 2013, 110 (21), 8690-8695.
24. Simon, V.; Bloch, N.; Landau, N. R. Intrinsic host restrictions to HIV-1 and mechanisms of viral escape. Nat. Immunol., 2015, 16 (6), 546-553.
25. Pery, E.; Sheehy, A.; Nebane, N. M.; Brazier, A. J.; Misra, V.; Rajendran, K. S.; Buhrlage, S. J.; Mankowski, M. K.; Rasmussen, L.; White, E. L.; Ptak, R. G.; Gabuzda, D. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein. J. Biol. Chem., 2015, 290 (16), 10504-10517.
26. Zhang, S.; Zhong, L.; Chen, B.; Pan, T.; Zhang, X.; Liang, L.; Li, Q.; Zhang, Z.; Chen, H.; Zhou, J.; Luo, H.; Zhang, H.; Bai, C. Identification of an HIV-1 replication inhibitor which rescues host restriction factor APOBEC3G in Vif-APOBEC3G complex. Antiviral Res., 2015, doi: 10.1016/j.antiviral.2015.07.009.
27. Cen, S.; Peng, Z. G.; Li, X. Y.; Li, Z. R.; Ma, J.; Wang, Y. M.; Fan, B.; You, X. F.; Wang, Y. P.; Liu, F.; Shao, R. G.; Zhao, L. X.; Yu, L.; Jiang, J. D. Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G. J. Biol. Chem., 2010, 285 (22), 16546-16552.
28. Abdool Karim, Q.; Abdool Karim, S. S.; Frohlich, J. A.; Grobler, A. C.; Baxter, C.; Mansoor, L. E.; Kharsany, A. B.; Sibeko, S.; Mlisana, K. P.; Omar, Z.; Gengiah, T. N.; Maarschalk, S.; Arulappan, N.; Mlotshwa, M.; Morris, L.; Taylor, D. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science, 2010, 329 (5996), 1168-1174.
29. Van Damme, L.; Ramjee, G.; Alary, M.; Vuylsteke, B.; Chandeying, V.; Rees, H.; Sirivongrangson, P.; Mukenge- Tshibaka, L.; Ettiegne-Traore, V.; Uaheowitchai, C.; Karim, S. S.; Masse, B.; Perriens, J.; Laga, M. Effectiveness of col-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: A randomised controlled trial. Lancet, 2002, 360 (9338), 971-977.
30. Van Damme, L.; Govinden, R.; Mirembe, F. M.; Guedou, F.; Solomon, S.; Becker, M. L.; Pradeep, B. S.; Krishnan, A. K.; Alary, M.; Pande, B.; Ramjee, G.; Deese, J.; Crucitti, T.; Taylor, D. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N. Engl. J. Med., 2008, 359 (5), 463-472.
31. Skoler-Karpoff, S.; Ramjee, G.; Ahmed, K.; Altini, L.; Plagianos, M. G.; Friedland, B.; Govender, S.; De Kock, A.; Cassim, N.; Palanee, T.; Dozier, G.; Maguire, R.; Lahteenmaki, P. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: A randomised, double-blind, placebo-controlled trial. Lancet, 2008, 372 (9654), 1977-1987.
32. Feldblum, P. J.; Adeiga, A.; Bakare, R.; Wevill, S.; Lendvay, A.; Obadaki, F.; Olayemi, M. O.; Wang, L.; Nanda, K.; Rountree, W. SAVVY vaginal gel (C31G) for prevention of HIV infection: A randomized controlled trial in Nigeria. PLoS One, 2008, 3 (1), e1474.
33. McCormack, S.; Ramjee, G.; Kamali, A.; Rees, H.; Crook, A. M.; Gafos, M.; Jentsch, U.; Pool, R.; Chisembele, M.; Kapiga, S.; Mutemwa, R.; Vallely, A.; Palanee, T.; Sookrajh, Y.; Lacey, C. J.; Darbyshire, J.; Grosskurth, H.; Profy, A.; Nunn, A.; Hayes, R.; Weber, J. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): A phase 3, randomised, double-blind, parallel-group trial. Lancet, 2010, 376 (9749), 1329-1337.
34. Guffey, M. B.; Richardson, B.; Husnik, M.; Makanani, B.; Chilongozi, D.; Yu, E.; Ramjee, G.; Mgodi, N.; Gomez, K.; Hillier, S. L.; Karim, S. A. HPTN 035 phase II/IIb randomised safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women. Sex. Transm. Infect., 2014, 90 (5), 363-369.
35. Grant, R. M.; Lama, J. R.; Anderson, P. L.; McMahan, V.; Liu, A. Y.; Vargas, L.; Goicochea, P.; Casapia, M.; Guanira-Carranza, J. V.; Ramirez-Cardich, M. E.; Montoya-Herrera, O.; Fernandez, T.; Veloso, V. G.; Buchbinder, S. P.; Chariyalertsak, S.; Schechter, M.; Bekker, L. G.; Mayer, K. H.; Kallas, E. G.; Amico, K. R.; Mulligan, K.; Bushman, L. R.; Hance, R. J.; Ganoza, C.; Defechereux, P.; Postle, B.; Wang, F.; McConnell, J. J.; Zheng, J. H.; Lee, J.; Rooney, J. F.; Jaffe, H. S.; Martinez, A. I.; Burns, D. N.; Glidden, D. V., Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med., 2010, 363 (27), 2587-2599.
36. Baeten, J. M.; Donnell, D.; Ndase, P.; Mugo, N. R.; Campbell, J. D.; Wangisi, J.; Tappero, J. W.; Bukusi, E. A.; Cohen, C. R.; Katabira, E.; Ronald, A.; Tumwesigye, E.; Were, E.; Fife, K. H.; Kiarie, J.; Farquhar, C.; John-Stewart, G.; Kakia, A.; Odoyo, J.; Mucunguzi, A.; Nakku-Joloba, E.; Twesigye, R.; Ngure, K.; Apaka, C.; Tamooh, H.; Gabona, F.; Mujugira, A.; Panteleeff, D.; Thomas, K. K.; Kidoguchi, L.; Krows, M.; Revall, J.; Morrison, S.; Haugen, H.; Emmanuel-Ogier, M.; Ondrejcek, L.; Coombs, R. W.; Frenkel, L.; Hendrix, C.; Bumpus, N. N.; Bangsberg, D.; Haberer, J. E.; Stevens, W. S.; Lingappa, J. R.; Celum, C. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N. Engl. J. Med., 2012, 367 (5), 399-410.
37. Thigpen, M. C.; Kebaabetswe, P. M.; Paxton, L. A.; Smith, D. K.; Rose, C. E.; Segolodi, T. M.; Henderson, F. L.; Pathak, S. R.; Soud, F. A.; Chillag, K. L.; Mutanhaurwa, R.; Chirwa, L. I.; Kasonde, M.; Abebe, D.; Buliva, E.; Gvetadze, R. J.; Johnson, S.; Sukalac, T.; Thomas, V. T.; Hart, C.; Johnson, J. A.; Malotte, C. K.; Hendrix, C. W.; Brooks, J. T. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N. Engl. J. Med., 2012, 367 (5), 423-434.
38. Choopanya, K.; Martin, M.; Suntharasamai, P.; Sangkum, U.; Mock, P. A.; Leethochawalit, M.; Chiamwongpaet, S.; Kitisin, P.; Natrujirote, P.; Kittimunkong, S.; Chuachoowong, R.; Gvetadze, R. J.; McNicholl, J. M.; Paxton, L. A.; Curlin, M. E.; Hendrix, C. W.; Vanichseni, S. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (The Bangkok Tenofovir Study): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet, 2013, 381 (9883), 2083-2090.
39. McCormack, S.; Dunn, D. Pragmatic open-label randomised trial of preexposure prophylaxis: The PROUD study. CROI 2015, Seattle, Washington, USA, February 23-26, 2015.
40. Palanee-Phillips, T.; Schwartz, K.; Brown, E. R.; Govender, V.; Mgodi, N.; Kiweewa, F. M.; Nair, G.; Mhlanga, F.; Siva, S.; Bekker, L. G.; Jeenarain, N.; Gaffoor, Z.; Martinson, F.; Makanani, B.; Naidoo, S.; Pather, A.; Phillip, J.; Husnik, M. J.; van der Straten, A.; Soto-Torres, L.; Baeten, J. Characteristics of women enrolled into a randomized clinical trial of dapivirine vaginal ring for HIV-1 prevention. PLoS One, 2015, 10 (6), e0128857.
41. Andrews, C. D.; Yueh, Y. L.; Spreen, W. R.; St Bernard, L.; Boente-Carrera, M.; Rodriguez, K.; Gettie, A.; Russell-Lodrigue, K.; Blanchard, J.; Ford, S.; Mohri, H.; Cheng-Mayer, C.; Hong, Z.; Ho, D. D.; Markowitz, M. A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge. Sci. Transl. Med., 2015, 7 (270), 270ra274.
42. van 't Klooster, G.; Hoeben, E.; Borghys, H.; Looszova, A.; Bouche, M. P.; van Velsen, F.; Baert, L. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a longacting injectable antiretroviral formulation. Antimicrob. Agents Chemother., 2010, 54 (5), 2042-2050.
43. Andrews, C. D.; Spreen, W. R.; Mohri, H.; Moss, L.; Ford, S.; Gettie, A.; Russell-Lodrigue, K.; Bohm, R. P.; Cheng-Mayer, C.; Hong, Z.; Markowitz, M.; Ho, D. D. Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science, 2014, 343 (6175), 1151-1154.
44. Coffin, J. M. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science, 1995, 267 (5197), 483-489.
45. Mulder, L. C.; Harari, A.; Simon, V. Cytidine deamination induced HIV-1 drug resistance. Proc. Natl. Acad. Sci. U.S.A., 2008, 105 (14), 5501-5506.
46. Kemal, K. S.; Ramirez, C. M.; Burger, H.; Foley, B.; Mayers, D.; Klimkait, T.; Hamy, F.; Anastos, K.; Petrovic, K.; Minin, V. N.; Suchard, M. A.; Weiser, B. Recombination between variants from genital tract and plasma: Evolution of multidrug-resistant HIV type 1. AIDS Res. Hum. Retroviruses, 2012, 28 (12), 1766-1774.
47. Solomon, D. A.; Sax, P. E. Current state and limitations of daily oral therapy for treatment. Curr. Opin. HIV. AIDS, 2015, 10 (4), 219-225.
48. Kumar, S.; Rao, P. S.; Earla, R.; Kumar, A. Drug-drug interactions between anti-retroviral therapies and drugs of abuse in HIV systems. Expert Opin. Drug. Metab. Toxicol., 2015, 11 (3), 343-355.
49. Phillips, A. N.; Dunn, D.; Sabin, C.; Pozniak, A.; Matthias, R.; Geretti, A. M.; Clarke, J.; Churchill, D.; Williams, I.; Hill, T.; Green, H.; Porter, K.; Scullard, G.; Johnson, M.; Easterbrook, P.; Gilson, R.; Fisher, M.; Loveday, C.; Gazzard, B.; Pillay, D. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS, 2005, 19 (5), 487-494.
50. Wensing, A. M.; Calvez, V.; Gunthard, H. F.; Johnson, V. A.; Paredes, R.; Pillay, D.; Shafer, R. W.; Richman, D. D. 2014 update of the drug resistance mutations in HIV-1. Top. Antivir. Med., 2014, 22 (3), 642-650.
51. Gupta, R. K.; Jordan, M. R.; Sultan, B. J.; Hill, A.; Davis, D. H.; Gregson, J.; Sawyer, A. W.; Hamers, R. L.; Ndembi, N.; Pillay, D.; Bertagnolio, S. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: A global collaborative study and meta-regression analysis. Lancet, 2012, 380 (9849), 1250-1258.
52. Rhee, S. Y.; Blanco, J. L.; Jordan, M. R.; Taylor, J.; Lemey, P.; Varghese, V.; Hamers, R. L.; Bertagnolio, S.; Rinke de Wit, T. F.; Aghokeng, A. F.; Albert, J.; Avi, R.; Avila-Rios, S.; Bessong, P. O.; Brooks, J. I.; Boucher, C. A.; Brumme, Z. L.; Busch, M. P.; Bussmann, H.; Chaix, M. L.; Chin, B. S.; D'Aquin, T. T.; De Gascun, C. F.; Derache, A.; Descamps, D.; Deshpande, A. K.; Djoko, C. F.; Eshleman, S. H.; Fleury, H.; Frange, P.; Fujisaki, S.; Harrigan, P. R.; Hattori, J.; Holguin, A.; Hunt, G. M.; Ichimura, H.; Kaleebu, P.; Katzenstein, D.; Kiertiburanakul, S.; Kim, J. H.; Kim, S. S.; Li, Y.; Lutsar, I.; Morris, L.; Ndembi, N.; Ng, K. P.; Paranjape, R. S.; Peeters, M.; Poljak, M.; Price, M. A.; Ragonnet- Cronin, M. L.; Reyes-Teran, G.; Rolland, M.; Sirivichayakul, S.; Smith, D. M.; Soares, M. A.; Soriano, V. V.; Ssemwanga, D.; Stanojevic, M.; Stefani, M. A.; Sugiura, W.; Sungkanuparph, S.; Tanuri, A.; Tee, K. K.; Truong, H. H.; van de Vijver, D. A.; Vidal, N.; Yang, C.; Yang, R.; Yebra, G.; Ioannidis, J. P.; Vandamme, A. M.; Shafer, R. W. Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: An individual-patient- and sequence-level metaanalysis. PLoS Med, 2015, 12 (4), e1001810.
53. WHO, Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. World Health Organisation Guidelines 2013. http://www.who.int/hiv/pub/guidelines/arv2013/en/ (Accessed August 7, 2015).
54. Pham, Q. D.; Wilson, D. P.; Law, M. G.; Kelleher, A. D.; Zhang, L. Global burden of transmitted HIV drug resistance and HIVexposure categories: A systematic review and meta-analysis. AIDS, 2014, 28 (18), 2751-2762.
55. Drescher, S. M.; von Wyl, V.; Yang, W. L.; Boni, J.; Yerly, S.; Shah, C.; Aubert, V.; Klimkait, T.; Taffe, P.; Furrer, H.; Battegay, M.; Ambrosioni, J.; Cavassini, M.; Bernasconi, E.; Vernazza, P. L.; Ledergerber, B.; Gunthard, H. F.; Kouyos, R. D. Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study. Clin. Infect. Dis., 2014, 58 (2), 285-294.
56. Mbisa, J. L.; Fearnhill, E.; Dunn, D. T.; Pillay, D.; Asboe, D.; Cane, P. A. Evidence of self-sustaining drug resistant HIV-1 lineages among untreated patients in the United Kingdom. Clin. Infect. Dis., 2015, May 19, pii: civ393. [Epub ahead of print]
57. Gunthard, H. F.; Aberg, J. A.; Eron, J. J.; Hoy, J. F.; Telenti, A.; Benson, C. A.; Burger, D. M.; Cahn, P.; Gallant, J. E.; Glesby, M. J.; Reiss, P.; Saag, M. S.; Thomas, D. L.; Jacobsen, D. M.; Volberding, P. A. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA, 2014, 312 (4), 410-425.
58. Roberts, T.; Bygrave, H.; Fajardo, E.; Ford, N. Challenges and opportunities for the implementation of virological testing in resource-limited settings. J. Int. AIDS. Soc., 2012, 15 (2), 17324.
59. Bhargava, M.; Cajas, J. M.; Wainberg, M. A.; Klein, M. B.; Pant Pai, N. Do HIV-1 non-B subtypes differentially impact resistance mutations and clinical disease progression in treated populations? Evidence from a systematic review. J. Intl. AIDS. Soc., 2014, 17, 18944.
60. Lehman, D. A.; Baeten, J. M.; McCoy, C. O.; Weis, J. F.; Peterson, D.; Mbara, G.; Donnell, D.; Thomas, K. K.; Hendrix, C. W.; Marzinke, M. A.; Frenkel, L.; Ndase, P.; Mugo, N. R.; Celum, C.; Overbaugh, J.; Matsen, F. A. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of singleor dual-agent preexposure prophylaxis. J. Infect. Dis., 2015, 211 (8), 1211-1218.
61. Parikh, U. M.; Mellors, J. W. HIV-1 drug resistance resulting from antiretroviral therapy far exceeds that from pre-exposure prophylaxis. Clin. Infect. Dis., 2012, 55 (2), 303-304.
62. Marrazzo, J. M.; Ramjee, G.; Richardson, B. A.; Gomez, K.; Mgodi, N.; Nair, G.; Palanee, T.; Nakabiito, C.; van der Straten, A.; Noguchi, L.; Hendrix, C. W.; Dai, J. Y.; Ganesh, S.; Mkhize, B.; Taljaard, M.; Parikh, U. M.; Piper, J.; Masse, B.; Grossman, C.; Rooney, J.; Schwartz, J. L.; Watts, H.; Marzinke, M. A.; Hillier, S. L.; McGowan, I. M.; Chirenje, Z. M. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med., 2015, 372 (6), 509-518.
63. Van Damme, L.; Corneli, A.; Ahmed, K.; Agot, K.; Lombaard, J.; Kapiga, S.; Malahleha, M.; Owino, F.; Manongi, R.; Onyango, J.; Temu, L.; Monedi, M. C.; Mak'Oketch, P.; Makanda, M.; Reblin, I.; Makatu, S. E.; Saylor, L.; Kiernan, H.; Kirkendale, S.; Wong, C.; Grant, R.; Kashuba, A.; Nanda, K.; Mandala, J.; Fransen, K.; Deese, J.; Crucitti, T.; Mastro, T. D.; Taylor, D. Preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med., 2012, 367 (5), 411-422.
64. Rees, H.; Delany-Moretlwe, S. A.; Lombard, C.; Baron, D.; Panchia, R.; Myer, l.; Schwartz, J. L.; Doncel, G. F.; Gray, G. FACTS 001 phase III trial of pericoital tenofovir 1% gel for HIV prevention in women. CROI 2015, Seattle, Washington, USA, February 23-26, 2015.
65. Abdool Karim, Q.; Abdool Karim, S. S.; Singh, B.; Short, R.; Ngxongo, S. Seroprevalence of HIV infection in rural South Africa. AIDS, 1992, 6 (12), 1535-1539.
66. UNAIDS Global report: UNAIDS report on the global AIDS epidemic 2013;http://www.unaids.org/en/resources/campaigns/globalreport2013/globalreport (Accessed August 8, 2015).
67. Anahtar, M. N.; Byrne, E. H.; Doherty, K. E.; Bowman, B. A.; Yamamoto, H. S.; Soumillon, M.; Padavattan, N.; Ismail, N.; Moodley, A.; Sabatini, M. E.; Ghebremichael, M. S.; Nusbaum, C.; Huttenhower, C.; Virgin, H. W.; Ndung'u, T.; Dong, K. L.; Walker, B. D.; Fichorova, R. N.; Kwon, D. S. Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract. Immunity, 2015, 42 (5), 965-976.
68. Masson, L.; Passmore, J. A.; Liebenberg, L. J.; Werner, L.; Baxter, C.; Arnold, K. B.; Williamson, C.; Little, F.; Mansoor, L. E.; Naranbhai, V.; Lauffenburger, D. A.; Ronacher, K.; Walzl, G.; Garrett, N. J.; Williams, B. L.; Couto-Rodriguez, M.; Hornig, M.; Lipkin, W. I.; Grobler, A.; Abdool Karim, Q.; Abdool Karim, S. S. Genital inflammation and the risk of HIV acquisition in women. Clin. Infect. Dis., 2015, 61 (2), 260-269.
69. Aldunate, M.; Srbinovski, D.; Hearps, A. C.; Latham, C. F.; Ramsland, P. A.; Gugasyan, R.; Cone, R. A.; Tachedjian, G. Antimicrobial and immune modulatory effects of lactic acid and short chain fatty acids produced by vaginal microbiota associated with eubiosis and bacterial vaginosis. Front. Physiol., 2015, 6, 164.
70. Hladik, F.; Burgener, A.; Ballweber, L.; Gottardo, R.; Vojtech, L.; Fourati, S.; Dai, J. Y.; Cameron, M. J.; Strobl, J.; Hughes, S. M.; Hoesley, C.; Andrew, P.; Johnson, S.; Piper, J.; Friend, D. R.; Ball, T. B.; Cranston, R. D.; Mayer, K. H.; McElrath, M. J.; McGowan, I. Mucosal effects of tenofovir 1% gel. eLife, 2015, 4.
71. Zalenskaya, I. A.; Joseph, T.; Bavarva, J.; Yousefieh, N.; Jackson, S. S.; Fashemi, T.; Yamamoto, H. S.; Settlage, R.; Fichorova, R. N.; Doncel, G. F. Gene expression profiling of human vaginal cells in vitro discriminates compounds with pro-inflammatory and mucosa-altering properties: Novel biomarkers for preclinical testing of HIV microbicide candidates. PLoS One, 2015, 10 (6), e0128557.
72. Hendrix, C. W.; Chen, B. A.; Guddera, V.; Hoesley, C.; Justman, J.; Nakabiito, C.; Salata, R.; Soto-Torres, L.; Patterson, K.; Minnis, A. M.; Gandham, S.; Gomez, K.; Richardson, B. A.; Bumpus, N. N. MTN-001: Randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One, 2013, 8 (1), e55013.
73. Woolhouse, M.; Farrar, J. Policy: An intergovernmental panel on antimicrobial resistance. Nature, 2014, 509 (7502), 555-557.